Efficacy of Signal Pathway Inhibitors Alone and in Combination With Cisplatin Varies Between Human Non-Small Cell Lung Cancer Lines

Journal of Surgical Research

Volumn 154, Issue 1, 2009, Pages 9-12

  Kilic, Arman ^a   Schuchert, Matthew J ^a   Luketich, James D ^a   Landreneau, Rodney J ^a   El Hefnawy, Talal ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

chemotherapy; lung cancer; non small cell lung cancer; oncology; signal pathway inhibitors; signal transduction inhibitors; targeted therapy; thoracic

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CELECOXIB; CISPLATIN; GEFITINIB; GOSSYPOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ARTICLE; ASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMONES; CISPLATIN; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GOSSYPOL; HUMANS; LUNG NEOPLASMS; MORPHOLINES; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 67349224204     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.05.022     Document Type: Article

References (15)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
2. SEER Cancer Statistics Review 1975-2004. http://seer.cancer.gov/csr/1975_2004/results_merged/topic_annualrates.pd f Accessed January 2008
3. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472
4. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031
5. Stabile L.P., Lyker J.S., Gubish C.T., et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65 (2005) 1459
6. Morelli M.P., Cascone T., Troiani T., et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208 (2006) 344
7. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284 (2003) 122
8. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237
9. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290 (2003) 2149
10. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: Results from a randomized, placebo-controlled, multicenter study (IRESSA Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527
11. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123
12. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129
13. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306
14. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497
15. Huang S.F., Liu H.P., Li L.H., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195